Prolonged release matrix tablet of pyridostigmine bromide: formulation and optimization using statistical methods.
The aim of this study was to design and optimize a prolonged release matrix formulation of pyridostigmine bromide, an effective drug in myasthenia gravis and poisoning with nerve gas, using hydrophilic - hydrophobic polymers via D-optimal experimental design. HPMC and carnauba wax as retarding agents as well as tricalcium phosphate were used in matrix formulation and considered as independent variables. Tablets were prepared by wet granulation technique and the percentage of drug released at 1 (Y(1)), 4 (Y(2)) and 8 (Y(3)) hours were considered as dependent variables (responses) in this investigation. These experimental responses were best fitted for the cubic, cubic and linear models, respectively. The optimal formulation obtained in this study, consisted of 12.8 % HPMC, 24.4 % carnauba wax and 26.7 % tricalcium phosphate, had a suitable prolonged release behavior followed by Higuchi model in which observed and predicted values were very close. The study revealed that D-optimal design could facilitate the optimization of prolonged release matrix tablet containing pyridostigmine bromide. Accelerated stability studies confirmed that the optimized formulation remains unchanged after exposing in stability conditions for six months.
School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. bolourchian@sbmu.ac.ir
Noushin
N
Bolourchian
Maryam
M
Rangchian
Seyed Mohsen
SM
Foroutan
D002626:Chemistry, Pharmaceutical; D002800:Cholinesterase Inhibitors / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004355:Drug Stability; D008962:Models, Theoretical; D011729:Pyridostigmine Bromide / Q000737:chemistry*; D012995:Solubility; D013607:Tablets
D002800:Cholinesterase Inhibitors; D003692:Delayed-Action Preparations; D013607:Tablets; D011729:Pyridostigmine Bromide